uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival
Show others and affiliations
2009 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, Vol. 50, no 9, 1512-1518 p.Article in journal (Refereed) Published
Abstract [en]

The p14ARF protein activates the p53 tumor suppressor by binding to and inhibiting its negative regulator HDM-2. We have studied the prognostic impact of p14ARF in acute myeloid leukemia (AML). Leukemic cells from 57 adult patients with normal karyotype de novo AML were analyzed for p14ARF mRNA expression level using real-time polymerase chain reaction (RT-PCR). We also tested the effect of conventional anti-leukemic drugs and the mutant p53-targeting small molecule PRIMA-1 in vitro. Patients whose cells expressed more p14ARF mRNA than the 75th percentile (0.26) had significantly better survival compared with those expressing lower levels, 61 vs. 30% 3-year survival (p = 0.046). The difference remained significant also when NPM1/FLT3 status was considered. The mean effects of all the tested conventional anti-leukemic drugs were greater in leukemic cell samples expressing p14ARF mRNA >or= 0.26, but the differences were not statistically significant. In contrast, PRIMA-1 had a significantly greater effect on leukemic cell samples with low levels of p14ARF mRNA. We conclude that low levels of p14ARF mRNA in leukemic cells from patients with normal karyotype AML is associated with poor prognosis. Treatment with drugs targeting p53 may be a future possibility to improve outcome for these patients.

Place, publisher, year, edition, pages
2009. Vol. 50, no 9, 1512-1518 p.
Keyword [en]
PRIMA-1, TP53, drug resistance, overall survival, NPM-1, FLT3
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-112091DOI: 10.1080/10428190903111914ISI: 000270552100019PubMedID: 19626541OAI: oai:DiVA.org:uu-112091DiVA: diva2:284903
Available from: 2010-01-08 Created: 2010-01-08 Last updated: 2010-07-02Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Rosenquist, Richard

Search in DiVA

By author/editor
Rosenquist, Richard
By organisation
Department of Genetics and Pathology
In the same journal
Leukemia and Lymphoma
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 664 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf